IMGC936 (an anti-ADAM9 antibody drug conjugate developed by MacroGenics) is undergoing Phase 1 investigations involving patients with TNBC, nonsquamous non-small cell lung cancer, colorectal cancer, gastroesophageal cancer, or pancreatic cancer (NCT04622774). Here, ADAM9 is linked to familial pancreatic carcinoma.